HomeInsurance appealsCigna · Saxenda

Cigna appeal guide

Cigna Saxenda coverage appeal

Cigna uses specific clinical-policy criteria for Saxenda. Most denials come from undocumented BMI history or missing step-therapy notes. Here is how to address both.

Cigna prior authorization criteria for Saxenda

  • BMI ≥30 (or ≥27 + comorbidity)
  • Lifestyle intervention documented ≥3 months
  • Specific comorbidity ICD-10 codes required (E66.x, I10, E11.x most common)
Cigna Saxenda policy bulletin

Step-by-step appeal flow

  1. 1

    Pull your carrier policy bulletin

    Cigna publishes its Saxenda coverage criteria. Read it first — every successful appeal cites it back to the reviewer.

  2. 2

    Document your medical necessity

    BMI ≥30 (or ≥27 + comorbidity) Lifestyle intervention documented ≥3 months Specific comorbidity ICD-10 codes required (E66.x, I10, E11.x most common)

  3. 3

    Have your prescriber submit the PA

    Most Cigna PAs go through CoverMyMeds or the carrier portal. Your prescriber attaches BMI history, comorbidities (with ICD-10 codes), lifestyle program participation, and prior weight-loss attempts.

  4. 4

    If denied — file the appeal within 60 days

    Cite Cigna Coverage Position Criteria PH-1518. Include ICD-10 codes verbatim in the letter.

  5. 5

    Submit external review if internal appeals fail

    After two internal appeals, you can request external review through your state insurance commissioner. ERISA plans go through the federal external-review process.

Letter template

Customizable Cigna appeal letter

We provide a generic medical-necessity letter generator. Customize with the Cigna-specific framing above for highest first-pass success.

Generate appeal letter
People also ask

Common questions readers ask

How does Wegovy compare to Saxenda?
Both are GLP-1 agonists from Novo Nordisk. Wegovy (semaglutide, weekly) produces ~15% mean weight loss; Saxenda (liraglutide, daily) produces ~6-8%. Wegovy is also cheaper per kg-lost, more convenient, and has cardiovascular outcome data (SELECT trial). Saxenda was first approved for adolescents (2020); Wegovy followed in 2022 — both are available for ages 12-17.
Full evidence-graded answer

Editorial information based on published Cigna coverage policies as of 2026. Your specific plan benefits may differ — confirm with your insurance card’s member services number. Not legal advice.